Compare Jabil Inc (JBL) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Medtronic PLC — how do they compare? Jabil Inc trades at $303.5 (market cap $31.38B), while Medtronic PLC trades at $87.57 (market cap $109.38B). The key difference: Medtronic PLC is far larger — about 3.5× Jabil Inc's market cap, and Medtronic PLC pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 23 Days and Medtronic PLC for 63 Days on average.
| JBL | MDT | |
|---|---|---|
Market Cap | $31.38B | $109.38B |
Volume | 1,418,629 | 55,890,185 |
Sector | Technology | Health |
52-Week High | $385.50 | $105.35 |
52-Week Low | $192.49 | $73.75 |
Typical Hold Time | 23 Days | 63 Days |
Enterprise Value | $33.66B | $128.71B |
Dividend Yield | 0.11% | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $299.47, down 3.14% today amid a bearish technical signal, though recent Q4 2026 earnings beat expectations with EPS of $4.40 versus $4.07 expected. The company shows strong fundamentals with revenue growth to $29.80B in 2025 and projected 24% growth in fiscal 2027 driven by AI infrastructure demand. Analyst consensus remains bullish with a $434.75 price target, representing 45% upside potential from current levels.
The stock presents a compelling growth opportunity with robust AI-driven expansion and strong institutional support, though technical weakness and market volatility pose near-term risks. With zero sell ratings and 61% buy recommendations, Wall Street sees significant upside despite recent price pressure from broader market sentiment.
Medtronic (MDT) trades at $87.75, up 0.76% on the day, with strong analyst support (60.78% buy ratings) and a $97.80 consensus price target suggesting 11.4% upside. The stock shows consistent earnings beats in recent quarters with Q3 2026 results pending, while technical indicators signal bearish momentum despite oversold RSI readings. Recent positive developments include FDA clearances for new medical technologies and a 49-year dividend growth streak with a current 3.2% yield.
MDT presents a compelling value opportunity with reasonable valuation multiples (P/E 21.06, P/S 2.93) and improving fundamentals, though technical weakness and competitive pressures warrant caution. The company's revenue growth acceleration to $33.54B in 2025 and strong cash flow generation support the dividend sustainability, while debt levels have increased to 31.11% of assets, representing a key monitoring point for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
